Длинная
HTBX Update
I see a cup and handle forecast called out here, which is a possibility with the way the current COVID market is moving.
HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction:
"PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially expressed by antigen-experienced T cells."
Another of which, a phase 1 COVID trial:
"Jeff Wolf, CEO of Heat, commented, "We remain on track to complete design and development of our COVID-19 vaccine in July, and expect that our gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with our partner, Waisman Biomanufacturing, in early August. Given our progress to date, we remain encouraged by the potential of our unique vaccine to provide broad cellular T-cell and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses.""
Each of these snippets made available via Yahoo.
Three options:
1) Sharp correction and continue to grow to higher highs
2) A bit of a prolonged correction, but still progress expected from the companies overall trends
3) Lower lows and a bust scenario
Trading stocks of this value is a very scary market, please do not take as financial advice and merely as informational.
HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction:
"PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially expressed by antigen-experienced T cells."
Another of which, a phase 1 COVID trial:
"Jeff Wolf, CEO of Heat, commented, "We remain on track to complete design and development of our COVID-19 vaccine in July, and expect that our gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with our partner, Waisman Biomanufacturing, in early August. Given our progress to date, we remain encouraged by the potential of our unique vaccine to provide broad cellular T-cell and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses.""
Each of these snippets made available via Yahoo.
Three options:
1) Sharp correction and continue to grow to higher highs
2) A bit of a prolonged correction, but still progress expected from the companies overall trends
3) Lower lows and a bust scenario
Trading stocks of this value is a very scary market, please do not take as financial advice and merely as informational.
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.